CARDIAC AND RESPIRATORY-FUNCTION AFTER BONE-MARROW TRANSPLANTATION IN CHILDREN WITH LEUKEMIA

被引:0
作者
ROVELLI, A
PEZZINI, C
SILVESTRI, D
TANA, F
GALLI, MA
UDERZO, C
机构
[1] UNIV MILAN,IST BIOMETRIA,MILAN,ITALY
[2] OSPED SAN GERARDO,DIV PNEUMOL,MONZA,ITALY
[3] OSPED SAN GERARDO,SERV CARDIOL,MONZA,ITALY
关键词
LEUKEMIA; BMT; LATE EFFECTS;
D O I
暂无
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Late cardiac and respiratory function changes were evaluated in children surviving disease-free more than 2 years after bone marrow transplantation (BMT) performed for haematological malignancies, Forty-one children received allogeneic and 10 autologous BMT. In all cases studied shortening fraction (SF) was always within normal limits from before BMT up to 4 years after BMT. SF, though still normal, was slightly lower in the group with higher pre-BMT cumulative anthracycline dose. Twenty-eight children underwent respiratory function tests regularly at all scheduled times (pre-BMT, +6 months, +1, +2, +3, +4 years after BMT). Vital capacity and total lung capacity showed a slight continuous decrease which was significant at 4 years after BMT (P = 0.015 and P = 0.003 respectively). The decline of forced expiratory volume 1s is observed 1 year after BMT (P = 0.002) was roughly maintained over time. However, no children complained of symptoms attributable to respiratory dysfunction, and all indices studied were always within normal limits in almost all patients. So far late cardiac and lung changes following BMT in children seem to be negligible. However, whether such abnormalities could further worsen and impair adult quality of life remains to be ascertained.
引用
收藏
页码:571 / 576
页数:6
相关论文
共 40 条
[1]   PROSPECTIVE COMPARATIVE-STUDY OF BONE-MARROW TRANSPLANTATION AND POSTREMISSION CHEMOTHERAPY FOR CHILDHOOD ACUTE MYELOGENOUS LEUKEMIA [J].
AMADORI, S ;
TESTI, AM ;
ARICO, M ;
COMELLI, A ;
GIULIANO, M ;
MADON, E ;
MASERA, G ;
RONDELLI, R ;
ZANESCO, L ;
MANDELLI, F .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (06) :1046-1054
[2]  
ARVIDSON J, 1994, BONE MARROW TRANSPL, V14, P117
[3]  
BADIER M, 1993, BONE MARROW TRANSPL, V12, P457
[4]   REGIMEN-RELATED TOXICITY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
BEARMAN, SI ;
APPELBAUM, FR ;
BUCKNER, CD ;
PETERSEN, FB ;
FISHER, LD ;
CLIFT, RA ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) :1562-1568
[5]  
Blatt J., 1993, PRINCIPLES PRACTICE, P1091
[6]   CYCLOPHOSPHAMIDE CARDIOTOXICITY IN BONE-MARROW TRANSPLANTATION - A PROSPECTIVE EVALUATION OF NEW DOSING REGIMENS [J].
BRAVERMAN, AC ;
ANTIN, JH ;
PLAPPERT, MT ;
COOK, EF ;
LEE, RT .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) :1215-1223
[7]   RISK-FACTORS FOR AIR-FLOW OBSTRUCTION IN RECIPIENTS OF BONE-MARROW TRANSPLANTS [J].
CLARK, JG ;
SCHWARTZ, DA ;
FLOURNOY, N ;
SULLIVAN, KM ;
CRAWFORD, SW ;
THOMAS, ED .
ANNALS OF INTERNAL MEDICINE, 1987, 107 (05) :648-656
[8]  
Cunningham I, 1992, Semin Respir Infect, V7, P132
[9]   LUNG-FUNCTION AFTER BONE-MARROW GRAFTING [J].
DEPLEDGE, MH ;
BARRETT, A ;
POWLES, RL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1983, 9 (02) :145-151
[10]   REPORT ON THE INTERNATIONAL WORKSHOP OF THE KIND-PHILIPP-FOUNDATION ON LATE EFFECTS AFTER BONE-MARROW TRANSPLANTATION IN CHILDHOOD MALIGNANCIES [J].
DOPFER, R ;
NIETHAMMER, D .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1993, 10 (01) :63-84